for the quarter and half year ended march, 2026 the statement of deviation under reg 32
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shukra Pharmaceuticals has filed a statement confirming there is NO deviation or variation in the utilisation of proceeds from its preferential issue of 46.43 lakh convertible warrants. The warrants were issued at Re. 1 per warrant for total consideration of ₹15.78 crore, as approved in an EGM held on 1 November 2025. The company received 25% upfront consideration of ₹3.94 crore (₹3,94,65,500) on 28 January 2026, as mandated under SEBI ICDR regulations. For the quarter ended March 2026, ₹3.94 crore was fully deployed towards working capital requirements, repayment of borrowings, capital expenditure and acquisitions in the same line of business, with an additional ₹0.024 lakh for general corporate purposes. The Audit Committee reviewed the utilisation and reported no comments or deviations.
The company has confirmed full and proper utilisation of the prefunded portion of the warrant issue proceeds with no deviations. This is a routine compliance filing and is positive from a governance standpoint, confirming fund deployment aligns with stated objects.